Psychiatric ADHD Follow-up Letter

Dear Dr. Sarah Jenkins, GP Name: John Smith DOB: 15/03/1990 CHI: 1234567890 Address: 10 Downing Street, London, SW1A 2AA Date: 01/11/2024 Location: Springfield Mental Health Clinic Present: Dr. Emily White (Psychiatrist), John Smith (Patient) Diagnosis: Attention-Deficit/Hyperactivity Disorder (ADHD), Combined Presentation, currently well-controlled. Current medication: * Elvanse 50mg, once daily in the morning * Sertraline 50mg, once daily Treatment plan changes: Dosage of Elvanse to be increased to 60mg daily, to be reviewed in 4 weeks. Referral for psychoeducation group therapy for ADHD management. Presenting Complaint: Mr. Smith presented for a routine follow-up regarding his ADHD management, reporting continued improvement in focus and reduction in hyperactivity but some lingering issues with task initiation and organisation. Clinical Summary: Medication response: Mr. Smith reports a good therapeutic response to Elvanse 50mg, noting significant improvements in his ability to concentrate during work tasks and a marked reduction in impulsivity and restlessness. He states that he is now able to sustain attention for longer periods and his workplace performance has improved. However, he continues to experience difficulties with initiating complex tasks and maintaining organisation for longer-term projects, suggesting there may still be room for dose optimisation. Medication compliance: Mr. Smith reports excellent compliance with both his Elvanse and Sertraline, taking them consistently as prescribed each morning. He uses a daily pill organiser to ensure adherence. Side effects: Mr. Smith reported mild appetite suppression in the initial weeks of starting Elvanse, which has largely resolved. He occasionally experiences a dry mouth, which he manages by increasing water intake. No other significant side effects were reported, and he denied any issues with sleep or cardiovascular symptoms. Specific benefits noticed: Mr. Smith highlighted improved focus during meetings, better control over impulsive spending, and an increased ability to listen actively in conversations. He also noted a reduction in his internal restlessness and fidgeting. Drug and alcohol use: Mr. Smith confirmed he does not use illicit drugs. He consumes alcohol socially, typically 1-2 units per week, which is unchanged and within recommended limits. He denies any concerns regarding his alcohol intake. Physical Health Monitoring: Date: 01/11/2024 Pulse: 72 bpm Pulse regularity: Regular Blood pressure: 128/78 mmHg Weight: 80 kg Weight change from last appointment: -1 kg (since last appointment 3 months ago) Mental State Examination: Appearance: Mr. Smith was casually dressed, well-groomed, and maintained good eye contact throughout the consultation. Behaviour: He was cooperative and engaged, with no signs of psychomotor agitation or retardation. He remained seated appropriately. Speech: Speech was of normal rate, volume, and tone, coherent and relevant. Thought form and content: Thought form was linear and goal-directed. Thought content was appropriate, with no evidence of delusions or obsessional thoughts. Mood symptoms: Mood was euthymic, and affect was congruent with mood, full range. Abnormal perceptions: Denied any abnormal perceptions, including hallucinations or illusions. Cognition: Alert and oriented to time, place, and person. Concentration and memory appeared intact during the consultation. Insight: Good insight into his ADHD diagnosis and the benefits of his current treatment, acknowledging the need for continued management. Risk Assessment: No reported thoughts of self-harm or suicide No reported irritability or aggression. No reported thoughts of harm to others No identified safeguarding concerns Any other relevant items: Mr. Smith mentioned an upcoming work promotion opportunity which he feels more confident pursuing due to his improved concentration and organisational skills. Formulation: Mr. Smith is a 34-year-old male with a diagnosis of ADHD, combined presentation, who has shown significant clinical improvement on Elvanse 50mg. Biologically, his response to stimulant medication supports the underlying neurobiological basis of his ADHD. Psychologically, he has developed improved coping strategies and self-awareness regarding his symptoms. Socially, his work performance and social interactions have improved, contributing to a better quality of life. Remaining challenges in task initiation and organisation suggest that further optimisation of his medication, alongside potential psychoeducation, could yield additional benefits. Impression: Mr. Smith's ADHD symptoms are largely well-controlled with his current medication, but there is still some functional impairment related to task initiation and organisation. We will proceed with a slight upward titration of Elvanse to 60mg daily and a referral for psychoeducation group therapy to further enhance his management strategies. This aims to consolidate his therapeutic gains and address the residual symptoms. Review planned in 4 weeks. Yours sincerely, Dr. Emily White, Consultant Psychiatrist